JP2024515920A5 - - Google Patents

Info

Publication number
JP2024515920A5
JP2024515920A5 JP2023540538A JP2023540538A JP2024515920A5 JP 2024515920 A5 JP2024515920 A5 JP 2024515920A5 JP 2023540538 A JP2023540538 A JP 2023540538A JP 2023540538 A JP2023540538 A JP 2023540538A JP 2024515920 A5 JP2024515920 A5 JP 2024515920A5
Authority
JP
Japan
Prior art keywords
cell
cells
domain
receptor
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023540538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515920A (ja
JP7701453B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/065550 external-priority patent/WO2023196994A1/en
Publication of JP2024515920A publication Critical patent/JP2024515920A/ja
Publication of JP2024515920A5 publication Critical patent/JP2024515920A5/ja
Priority to JP2025031958A priority Critical patent/JP2025105605A/ja
Application granted granted Critical
Publication of JP7701453B2 publication Critical patent/JP7701453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023540538A 2022-04-08 2023-04-07 固形腫瘍標的化骨格を有する細胞及びその使用 Active JP7701453B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025031958A JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263329364P 2022-04-08 2022-04-08
US63/329,364 2022-04-08
US202263380378P 2022-10-20 2022-10-20
US63/380,378 2022-10-20
PCT/US2023/065550 WO2023196994A1 (en) 2022-04-08 2023-04-07 Cells having solid tumor targeting backbone and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025031958A Division JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Publications (3)

Publication Number Publication Date
JP2024515920A JP2024515920A (ja) 2024-04-11
JP2024515920A5 true JP2024515920A5 (enExample) 2024-08-15
JP7701453B2 JP7701453B2 (ja) 2025-07-01

Family

ID=88243835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023540538A Active JP7701453B2 (ja) 2022-04-08 2023-04-07 固形腫瘍標的化骨格を有する細胞及びその使用
JP2025031958A Pending JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025031958A Pending JP2025105605A (ja) 2022-04-08 2025-02-28 固形腫瘍標的化骨格を有する細胞及びその使用

Country Status (10)

Country Link
US (2) US20250228943A1 (enExample)
EP (1) EP4504914A4 (enExample)
JP (2) JP7701453B2 (enExample)
KR (1) KR20250005097A (enExample)
CN (1) CN119256075A (enExample)
AU (1) AU2023249802A1 (enExample)
CA (1) CA3247423A1 (enExample)
IL (1) IL316101A (enExample)
MX (1) MX2024008227A (enExample)
WO (1) WO2023196994A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098914A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
JP2024539013A (ja) * 2021-10-20 2024-10-28 フェイト セラピューティクス，インコーポレイティド 固形腫瘍における同種異系養子細胞療法のためのエフェクター細胞及びその使用
IL312565A (en) * 2021-11-08 2024-07-01 Fate Therapeutics Inc Engineered effector cells for trafficking of allogeneic cell therapies in solid tumors
WO2025101809A1 (en) * 2023-11-08 2025-05-15 Fate Therapeutics, Inc. Ipsc-derived t cells for solid tumor treatment

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
IL305629A (en) 2013-02-15 2023-11-01 Univ California Chimeric antigen receptor and methods of using it
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
EP3104866A4 (en) 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
DK3105335T3 (da) 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
CN120536341A (zh) 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
AU2015312117A1 (en) 2014-09-02 2017-03-02 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016149665A1 (en) 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
ES2909973T3 (es) * 2015-11-04 2022-05-10 Hope City Receptores quiméricos para el antígeno que se dirigen a HER2
CA3007473A1 (en) 2015-12-14 2017-06-22 Bellicum Pharmaceuticals, Inc. Dual controls for therapeutic cell activation or elimination
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US12247226B2 (en) 2017-10-11 2025-03-11 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) * 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
EP3824075A4 (en) * 2018-07-17 2022-04-20 The Regents of The University of California CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
EP3848387A4 (en) * 2018-09-05 2022-06-22 Kong, Seogkyoung CHIMERIC ANTIGEN RECEPTOR FOR SOLID TUMOR AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR
WO2020092057A1 (en) * 2018-10-30 2020-05-07 Yale University Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells
JP2022525928A (ja) * 2019-03-21 2022-05-20 ガミダ セル リミテッド 併用療法における移植に適したｎｋ細胞画分の増殖及び増殖ｎｋ細胞画分の使用
EP3941947A4 (en) 2019-03-22 2022-12-14 Olivia Newton-John Cancer Research Institute ANTI-HER2 BINDING MOLECULES
WO2020197319A1 (ko) * 2019-03-28 2020-10-01 한국생명공학연구원 면역세포의 제조방법 및 그의 용도
KR20220035190A (ko) * 2019-07-17 2022-03-21 페이트 세러퓨틱스, 인코포레이티드 면역 효과기 세포 조작 및 이의 용도
US20220378831A1 (en) * 2019-09-25 2022-12-01 Fate Therapeutics, Inc. Multi-targeting effector cells and use thereof
EP4041759A4 (en) * 2019-10-07 2023-12-20 Fate Therapeutics, Inc. IMPROVED CHIMERIC ANTIGEN RECEPTOR FOR IMMUNE EFFECTIVE CELL ENGINEERING AND ITS USE
EP4045539A4 (en) * 2019-10-17 2024-03-13 Fate Therapeutics, Inc. Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス，インコーポレイテッド 小化合物を使用するｉＰＳＣ由来エフェクター免疫細胞の増強
CN115485293A (zh) 2020-01-23 2022-12-16 埃克苏马生物技术公司 用于her2的嵌合抗原受体和其使用方法
US11230699B2 (en) * 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2021235894A1 (en) 2020-05-22 2021-11-25 Green Cross Lab Cell Corporation Anti-HER2 Antibody or Antigen-binding Fragment thereof, and Chimeric Antigen Receptor Comprising Same
US20230405121A1 (en) * 2020-11-04 2023-12-21 Fate Therapeutics, Inc. Engineered ipsc and immune effector cells for heterogenous tumor control
WO2022098914A1 (en) * 2020-11-04 2022-05-12 Fate Therapeutics, Inc. Engineered ipsc and persistent immune effector cells
CN112391414A (zh) 2020-11-17 2021-02-23 中国医学科学院基础医学研究所 一种靶向her2的car-t表达载体及其构建和应用
EP4253420A4 (en) * 2020-11-30 2024-11-06 ONO Pharmaceutical Co., Ltd. HER2 TARGETING AGENT
KR20250004622A (ko) * 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체

Similar Documents

Publication Publication Date Title
AU2021201679B2 (en) Transgene genetic tags and methods of use
JP2022541441A5 (enExample)
JP2022550899A5 (enExample)
KR20210053318A (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
JP2022548943A5 (enExample)
US20180319862A1 (en) Chimeric receptors containing traf-inducing domains and related compositions and methods
JP2021505131A5 (enExample)
JP2022510207A5 (enExample)
KR20230129983A (ko) 조작된 세포 요법을 위한 표적화된 사이토카인 구축물
JP2023505206A5 (enExample)
KR20230007559A (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
WO2020057641A1 (zh) 表达有趋化因子的细胞及用途
EP3822345A1 (en) Genetically engineered cell and application thereof
KR20190104528A (ko) Car-t 세포들 투여를 결정하는 방법
JP2023548467A5 (enExample)
KR20210059715A (ko) 통합된 핵산 평가 방법
JP2023545992A5 (enExample)
EP4182337B1 (en) Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
KR20260013488A (ko) 면역 이펙터 세포 및 이의 용도
RU2024129913A (ru) Клетки, имеющие нацеленный на солидную опухоль каркас, и их применение
RU2822461C1 (ru) Трансгенные генетические метки и способы применения
EA050762B1 (ru) Аллогенные терапевтические клетки
HK40069668A (en) Transgene genetic tags and methods of use
HK1233273B (en) Transgene genetic tags and methods of use